A 52-week, double-blind, randomised, multi-centre, phase III, parallel-group study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 mcg as needed compared with Pulmicort (budesonide) Turbuhaler 200 mcg twice daily plus terbutaline Turbuhaler 0.4 mg as needed

Trial Profile

A 52-week, double-blind, randomised, multi-centre, phase III, parallel-group study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 mcg as needed compared with Pulmicort (budesonide) Turbuhaler 200 mcg twice daily plus terbutaline Turbuhaler 0.4 mg as needed

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Budesonide; Terbutaline
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms SYGMA 2
  • Sponsors AstraZeneca
  • Most Recent Events

    • 06 Jul 2016 Status changed from recruiting to active, no longer recruiting.
    • 15 Jan 2016 Planned End Date changed from 1 May 2017 to 1 Aug 2017 as reported by ClinicalTrials.gov record.
    • 15 Jan 2016 Planned primary completion date changed from 1 May 2017 to 1 Aug 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top